WO2002068632A3 - Methods to identify mutant cells with altered sialic acid - Google Patents

Methods to identify mutant cells with altered sialic acid Download PDF

Info

Publication number
WO2002068632A3
WO2002068632A3 PCT/US2002/005455 US0205455W WO02068632A3 WO 2002068632 A3 WO2002068632 A3 WO 2002068632A3 US 0205455 W US0205455 W US 0205455W WO 02068632 A3 WO02068632 A3 WO 02068632A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sialic acid
mutant cells
identify mutant
altered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/005455
Other languages
French (fr)
Other versions
WO2002068632A2 (en
Inventor
Yoshihiro Kawaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to EP02724994A priority Critical patent/EP1364006A2/en
Publication of WO2002068632A2 publication Critical patent/WO2002068632A2/en
Publication of WO2002068632A3 publication Critical patent/WO2002068632A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides cells useful to propagate influenza virus mutants having reduced sialidase activity.
PCT/US2002/005455 2001-02-23 2002-02-22 Methods to identify mutant cells with altered sialic acid Ceased WO2002068632A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02724994A EP1364006A2 (en) 2001-02-23 2002-02-22 Methods to identify mutant cells with altered sialic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27104401P 2001-02-23 2001-02-23
US60/271,044 2001-02-23

Publications (2)

Publication Number Publication Date
WO2002068632A2 WO2002068632A2 (en) 2002-09-06
WO2002068632A3 true WO2002068632A3 (en) 2003-05-30

Family

ID=23033961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005455 Ceased WO2002068632A2 (en) 2001-02-23 2002-02-22 Methods to identify mutant cells with altered sialic acid

Country Status (3)

Country Link
US (2) US7176021B2 (en)
EP (1) EP1364006A2 (en)
WO (1) WO2002068632A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105695393A (en) * 2016-03-24 2016-06-22 友康恒业生物科技（北京）有限公司 MDCK cell serum-free culture medium and purpose and preparation thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364006A2 (en) * 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
JP2009532352A (en) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション High titer recombinant influenza virus for vaccine
US9662383B2 (en) * 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines
WO2008147496A2 (en) * 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2296701A1 (en) * 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
JP2013507990A (en) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション High-titer recombinant influenza virus with enhanced replication in Vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN106995802B (en) 2011-06-24 2021-04-09 复尔健有限公司 Influenza virus mutants and their uses
ES2655051T3 (en) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Influenza virus with mutant PB2 gene segment as live attenuated vaccines
JP2016524915A (en) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション High titer recombinant influenza virus with enhanced replication in MDCK, Vero cells or eggs
US9757446B2 (en) 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2017040203A1 (en) 2015-08-28 2017-03-09 Yoshihiro Kawaoka Generation of infectious influenza viruses from virus-like particles
JP2019510481A (en) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション Improved influenza B virus replication for vaccine development
CN110573614B (en) 2017-02-27 2024-03-29 复尔健有限公司 Immunogenic compositions against influenza
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (en) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) Improved influenza virus replication for vaccine development
EP3980060A4 (en) 2019-06-07 2023-04-12 Flugen, Inc. FLU VIRUS SKELETON
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (en) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant influenza virus with stabilized NA
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2022020469A1 (en) 2020-07-21 2022-01-27 Flugen, Inc. Influenza virus backbone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2061A (en) * 1841-04-24 Spring-lancet
US231348A (en) * 1880-08-17 Alfeed nobel
JP3484215B2 (en) * 1994-01-27 2004-01-06 花王株式会社 Chinese hamster ovary cell mutant
US6843996B1 (en) 1995-06-05 2005-01-18 Medimmune Vaccines, Inc. Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
AU782624B2 (en) * 1999-12-30 2005-08-18 Board Of Trustees Of Miami University Methods and compositions for inhibiting adhesion by microorganisms
EP1364006A2 (en) 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
EP3009507B1 (en) 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
KR20070100882A (en) 2004-11-11 2007-10-12 솔베이 파마슈티칼스 비. 브이 Defective Influenza Virus Particles
JP2009532352A (en) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション High titer recombinant influenza virus for vaccine
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUGHES MARK T ET AL: "Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity.", JOURNAL OF VIROLOGY, vol. 75, no. 8, April 2001 (2001-04-01), pages 3766 - 3770, XP002232422, ISSN: 0022-538X *
HUGHES MARK T ET AL: "Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice.", JOURNAL OF VIROLOGY, vol. 74, no. 11, June 2000 (2000-06-01), pages 5206 - 5212, XP002232424, ISSN: 0022-538X *
MASUDA H ET AL: "Substitution of amino acid residue in influenza A virus hemagglutinin affects recognition of sialyl-oligosaccharides containing N-glycolylneuraminic acid", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 464, no. 1-2, 24 December 1999 (1999-12-24), pages 71 - 74, XP004260724, ISSN: 0014-5793 *
NEUMANN G ET AL: "Generation of influenza A viruses entirely from cloned cDNAs", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 16, 3 August 1999 (1999-08-03), pages 9345 - 9350, XP002151639, ISSN: 0027-8424 *
SCHULTZ-CHERRY STACEY ET AL: "Influenza virus NS1 protein induces apoptosis in cultured cells.", JOURNAL OF VIROLOGY, vol. 75, no. 17, September 2001 (2001-09-01), pages 7875 - 7881, XP002232423, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105695393A (en) * 2016-03-24 2016-06-22 友康恒业生物科技（北京）有限公司 MDCK cell serum-free culture medium and purpose and preparation thereof

Also Published As

Publication number Publication date
WO2002068632A2 (en) 2002-09-06
US8679819B2 (en) 2014-03-25
US7176021B2 (en) 2007-02-13
US20080009031A1 (en) 2008-01-10
US20020197705A1 (en) 2002-12-26
EP1364006A2 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
WO2002092797A3 (en) Alpha-amylase variant with altered properties
AU2002352024A1 (en) Profiling of the immune gene repertoire
AU2003211255A1 (en) Method of manufacturing glass panel, and glass panel manufactured by the method
AU2002324580A1 (en) Compositions and methods relating to the daptomycin biosynthetic gene cluster
CA2534829A1 (en) Modular floor
AU2002345839A1 (en) Gene expression alterations underlying the retardation of aging by caloric restriction in mammals
AU2001278323A1 (en) Modified sialic acid vaccines
AU2003245663A1 (en) Process for the enzymatic resolution of 1,3-dioxolane-4-carboxylates
AU2001268163A1 (en) Haplotypes of the ube3a gene
AU2001253521A1 (en) Haplotypes of the cxcr4 gene
AU2002359990A1 (en) Intermediate and process for producing optically active compound from the intermediate
AU2002254940A1 (en) Combination of nateglinide or repaglinide with at least one further antidiabetic compound
AU2002365903A1 (en) Method for the generation of proteins with new enzymatic function
AU2003227049A1 (en) Viral mutants, manipulated in the furin cleavage sites of glycoproteins
AU2003288727A1 (en) Plate applicable to surfaces, particularly walls or glass panes
AU2002329603A1 (en) Biogenic fpa: enzymatic production of formylphosphonic acid by the oxidation of hydroxymethylphosphonic acid
AU2001254780A1 (en) Mammalian heparanase
AU2001284736A1 (en) Haplotypes of the pla2g1b gene
AU2292999A (en) Connectors of plane surfaces suitable for construction of furniture by assembly
AU2002356750A1 (en) Method for the production of oxymethylene homo- or co-polymers
AU2002211920A1 (en) Haplotypes of the fy gene
AU2001249798A1 (en) Haplotypes of the ccr5 gene
AU2002213489A1 (en) Haplotypes of the cyp27a1 gene
AU2002236570A1 (en) Haplotypes of the pon1 gene
AU2001272981A1 (en) Haplotypes of the slc26a2 gene

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2002724994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002724994

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP